Deregulated angiogenesis has been identified as a key contributor in a number of
pathological conditions including cancer. It is a complex process, which involves highly …

Anti-angiogenesis therapy, by blocking formation of new blood vessels in tumors, is the
standard-of-care therapy for various cancer types. The classic concept of anti-angiogenesis …

A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary
tumour growth and the formation of metastasis depend on the establishment of new blood …

The great interest in the potential antineoplastic effect of targeting tumor-associated blood
vessels has generated an expanding armamentarium of therapeutic tools that include …

Angiogenesis inhibitors belong to a new class of drugs. Many of these drugs are in clinical
trials to treat cancer, while others have recently received FDA approval. However …

Drugs that block angiogenesis are important components of first-line therapies for a number
of human cancers. However, some of these agents have undesirable effects on the patient …

Angiogenesis is crucial for tumour growth and the formation of metastases. Various classes
of angiogenesis inhibitors that are each able to inhibit one of the various steps of this …

Tumor growth requires induction of an angiogenic program, and targeting of this program
with antiangiogenic drugs shows an impact on tumor progression. However, although they …

A large body of evidence now demonstrates that angiostatic therapy represents a promising
way to fight cancer. This research recently resulted in the approval of the first angiostatic …

Angiogenesis is the development of new blood vessels from the existing vascular bed. In
normal conditions this tightly regulated process occurs only during embryonic development …